Delivering RNA-targeted drugs to partners and collaborators, today
Santaris Pharma A/S is rapidly becoming the preferred partner for the development of RNA-targeted medicines having established partnerships with five pharmaceutical companies over the past five years. These partnerships further validate the broad utility of the Santaris Pharma A/S LNA Drug Platform and Drug Discovery Engine to develop effective and well tolerated LNA-based drugs across multiple disease areas for its partners.
Partnerships are a critical element of the Company's strategy to leverage its LNA Drug Platform and Drug Discovery Engine to deliver on the promise of RNA-targeted drugs, today.
Key elements of the existing partnerships include
- Exclusivity on targets, not therapeutic areas
- Design and selection from optimal drug candidates
- Shared responsibility for further development (pharmacology, toxicology, late stage preclinical and clinical)
- Access and exclusivity research FTEs and downstream milestones and royalties
Delivering RNA-targeted drugs to partners and collaborators, today
- Five major partnerships in last five years
- Partnerships to date that cover more than 25 different potential targets, residing in many different tissues and involved in a diversity of diseases, including infectious and inflammatory diseases, metabolic disorders, cancer and rare genetic disorders.
- Delivered drug candidates against 10 different targets
- Two partnered programs currently in clinical development
 |
miRagen collaboration (2010) - drug candidates against a limited number of microRNA targets for the treatment of cardiovascular disease
- miRagen licenses rights to utilize LNA Drug Platform for specific microRNA targets implicated in CV disease
- Santaris Pharma A/S received a minority equity interest in miRagen, eligible to receive milestone payments and royalties
|
 |
Shire collaboration (2009) - lead candidates against up to five targets
- Santaris Pharma A/S responsible for design and selection of lead candidates
- Shire responsible for pharmacology and further development
- Upfront/milestones in excess of $380m, FTE funding; undisclosed royalties
- Worldwide commercial rights partnered
|
 |
Pfizer collaboration (2008) - lead candidates against up to 10 targets
- Santaris Pharma A/S responsible for design and delivery of lead candidates
- Pfizer responsible for pharmacology and further development
- Upfront/milestones in excess of $800m; FTE funding; and double-digit royalties
- Worldwide commercial rights partnered
|
 |
GSK collaboration (2007) - GSK options to drug candidates from up to four viral disease programs
- Santaris Pharma A/S responsible for development to completion of phase 2a trials
- Upfront/milestones in excess of $700m; double-digit royalties
- Worldwide commercial rights partnered
|
 |
Enzon collaboration (2006) - lead candidates against eight cancer targets
- Two clinical stage programs; Development of lead candidates against six additional cancer targets
- All six drug candidates designed, synthesized and selected within 24 months of signing agreement
- Upfront / milestones in excess of $200m; high single-digit royalties
- Santaris Pharma A/S retains commercial rights in Europe; milestones and royalties worldwide
|
